General Research Model: human

Efficacy and Safety of Hydrogen Therapy in Patients with Early-Stage Interstitial Lung Disease: A Single-Center, Randomized, Parallel-Group Controlled Trial

Simplified Version Available

Can Hydrogen Therapy Help People with Lung Disease Breathe Easier?

A recent study found that hydrogen therapy is a promising treatment for interstitial lung disease, with fewer side effects than traditional treatments. The study compared hydrogen therapy to N-Acetylcysteine and found that it was just as effective in improving lung function and reducing inflammation. This could lead to new, safer treatment options for people with ILD.

Read Simplified Article

Abstract

Publish Year 2023 Country China Rank Positive Journal Therapeutics and Clinical Risk Management Primary Topic Lung Secondary TopicInterstitial Lung Disease Model Human Tertiary TopicOxidative Stress Vehicle Gas pH N/A Application Inhalation Comparison N-Acetylcysteine (NAC) Complement

Results

Conclusion: Hydrogen therapy exhibits superior efficacy and acceptable safety compared with NAC therapy in patients with early-stage ILD.

Purpose

Results: The rate of HRCT image improvement from the baseline in the HW group (63.6%) was higher than that in the NAC group (39.5%). A significant decrease in CPI and improvement in DLCO-sb were observed in the hydrogen group compared with those in the control group. Changes in other pulmonary function parameters, including FVC, FEV1, FEV1/FVC%, and TLC, were not significantly different between the two groups. Adverse events were reported in 7 (15.9%) patients in the HW group and 10 (23.3%) patients in the NAC group, but the difference was not significant (P=0.706).